King Pharmaceuticals announces FDA approval of new Bicillin[R] manufacturing facility.
The recent Sexually Transmitted Diseases Treatment Guidelines issued in 2006 by the Centers for Disease Control and Prevention (CDC) recommends penicillin G as the preferred treatment of all stages of syphilis. Bicillin[R] L-A, administered via deep intramuscular injection, has been used effectively for more than 60 years to cure syphilis and prevent sexual transmission.
"This modern facility demonstrates King's commitment to the continued importance of treating and controlling infectious diseases," stated Eric J. Bruce, Chief Technical Operations Officer, King Pharmaceuticals, Inc. "With syphilis on the rise in major cities across the U.S., the new facility expands our production capacity to ensure continued availability of Bicillin[R] L-A to healthcare providers and patients."
To streamline the ease and use of Bicillin[R] L-A, King is now using the Becton Dickinson Hypack Luer-Lok syringe system with the Eclipse safety-cover needle. The Bicillin[R] L-A package carton contains five prefilled syringes per thermoform tray, two trays per carton and 10 needles individually sterilized and packaged.
Bicillin[R] L-A is available in 1 mL Pediatric (600,000 units), 2mL (1,200,000 units) and 4mL (2,400,000 units). The average dose to treat primary, secondary and latent syphilis is 2,400,000 units in one single dose. Bicillin[R] L-A is also indicated for mild-to-moderate infections of the upper respiratory tract due to susceptible streptococci, including streptococcal pharyngitis, and has been used for prophylaxis to prevent recurrence of rheumatic fever and/or chorea.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Industry News|
|Date:||Mar 1, 2007|
|Previous Article:||Nortec announces FDA approval of its generic Inderal-La Licensed to Par Pharmaceutical.|
|Next Article:||PDUFA public forum previews hill debate.|